Safety and Efficacy of Glucagon‐Like Peptide‐1 Receptor Agonists Use in Elderly People With Obesity—A Meta‐Analysis
Obesity · 2026-09 · 34 (S2) · 25-35
DOI: 10.1002/oby.70098 ↗At a glance
Metaanalyse in Obesity, published online on 2026-02-04. Written by Inês Rego de Figueiredo and 4 co-authors. Institution: Multidisciplinary Unit of Bariatric and Metabolic Surgery, Curry Cabral Hospital, Unidade Local de Saúde São José, Centro Clínico Académico de Lisboa…. Major MEDLINE topics: Glucagon-Like Peptide-1 Receptor Agonists, Obesity, Hypoglycemic Agents. Cited 13 times so far (Crossref); 16 references. The full text is freely available (open access, CC BY-NC-ND 4.0).
Abstract (original language)
Objective
This meta‐analysis evaluates the safety and efficacy of glucagon‐like peptide‐1 receptor agonists (GLP‐1 RA) for the treatment of older adults with obesity compared to younger individuals.
Methods
A systematic review was conducted following PRISMA guidelines (PROSPERO CRD420251074381). PubMed, Embase, and Scopus were searched until May 17, 2025, for randomized controlled trials and observational studies assessing GLP‐1 RA in adults ≥ 65 years with obesity with or without type 2 diabetes. Random effects meta‐analyses calculated the log odds ratios (LOR) for dichotomous outcomes and the mean differences (MD) for continuous outcomes, with equivalence testing via two one‐sided tests (TOST) and meta‐regression for baseline adjustments.
Results
Five studies involving 1229 participants were included. No significant difference in serious adverse events was found between older and younger adults (pooled LOR: 0.06, p = 0.9). Older adults had a trend toward lower frequency of nausea (LOR: −0.44, p = 0.06) but higher incidence of constipation (LOR: 0.72, p = 0.02) and hypoglycemia (LOR: 0.97, p < 0.001). Efficacy in metabolic and weight control was comparable. Additionally, one study suggested that liraglutide could reduce fat mass without worsening sarcopenia.
Conclusions
GLP‐1 RA therapy seems to be safe and effective in older adults with obesity, achieving similar effects on weight loss and glycemic control as in younger individuals.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Multidisciplinary Unit of Bariatric and Metabolic Surgery, Curry Cabral Hospital, Unidade Local de Saúde São José, Centro Clínico Académico de Lisboa, Lisbon, Portugal.
- Egas Moniz School of Health and Science, Almada, Portugal.
- NOVA Medical School/Faculdade de Ciencias Medicas, New University of Lisbon, Lisbon, Portugal.
- Department of Nutrition, Curry Cabral Hospital, Unidade Local de Saúde São José, Centro Clínico Académico de Lisboa, Lisbon, Portugal.
- Department of Internal Medicine, Hospital Garcia de Orta, Unidade Local de Saúde Almada-Seixal, Almada, Portugal.
- Department of Endocrinology, Diabetes, and Metabolism, Curry Cabral Hospital, Unidade Local de Saúde São José, Centro Clínico Académico de Lisboa, Lisbon, Portugal.
ORCID profiles: Inês Rego de Figueiredo
Cite
APA
Rego de Figueiredo, I., Simas, F. S., Ghiletchi, A., Oliveira Torres, J., & Silva-Nunes, J. (2026). Safety and Efficacy of Glucagon‐Like Peptide‐1 Receptor Agonists Use in Elderly People With Obesity—A Meta‐Analysis. Obesity, 34(S2), 25-35. https://doi.org/10.1002/oby.70098
Vancouver
Rego de Figueiredo I, Simas FS, Ghiletchi A, Oliveira Torres J, Silva-Nunes J. Safety and Efficacy of Glucagon‐Like Peptide‐1 Receptor Agonists Use in Elderly People With Obesity—A Meta‐Analysis. Obesity. 2026;34(S2):25-35. doi:10.1002/oby.70098
BibTeX
@article{RegodeFigueiredo2026,
author = {Rego de Figueiredo, Inês and Simas, Filipa Sofia and Ghiletchi, Angela and Oliveira Torres, João and Silva-Nunes, José},
title = {Safety and Efficacy of Glucagon‐Like Peptide‐1 Receptor Agonists Use in Elderly People With Obesity—A Meta‐Analysis},
journal = {Obesity},
year = {2026},
volume = {34},
number = {S2},
pages = {25--35},
doi = {10.1002/oby.70098}
}
EUVIMED